Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 11/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8392811 | 0.80 | KMT2A (0.46) | FFAR2PTGESFDPSALDH1A1POLB | |
| SCHEMBL16814871 | 0.77 | TUBB4A (0.46) | FFAR2FDPSALDH1A1POLBHPGDS | |
| SCHEMBL3639659 | 0.75 | HPGDS (0.46) | FFAR2PTGESFDPSALDH1A1HPGDS | |
| SCHEMBL3765674 | 0.74 | LMNA (0.43) | ALDH1A1 | |
| SCHEMBL3771979 | 0.74 | ALDH1A1 (0.37) | ALDH1A1POLB | |
| SCHEMBL2698206 | 0.73 | ATR (0.43) | FFAR2PTGESFDPSHPGDSNR3C1 | |
| SCHEMBL17097345 | 0.72 | THRB (0.41) | FFAR2PTGESFDPSALDH1A1POLB | |
| SCHEMBL31169779 | 0.72 | HPGDS (0.41) | FFAR2PTGESFDPSALDH1A1HPGDS | |
| SCHEMBL8109606 | 0.71 | — | — | |
| SCHEMBL29396830 | 0.71 | ALDH1A1 (0.37) | ALDH1A1POLBGABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124824-B1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-6849646-B1 | Chromenone and chromanone derivatives as integrin inhibitors | MERCK PATENT GMBH (DE) | 2005-02-01 | — | — | US | disclosed |
| US-20040138284-A1 | Indol-3-yl derivatives | WIESNER MATTHIAS | 2004-07-15 | — | — | US | disclosed |
| US-6743810-B2 | INTEGRIN INHIBITORS; TUMORS, OSTEOPOROSIS, OSTEOLYTIC DISEASES, SUPPRESSING ANGIOGENESIS, ANTITHROMBOTIC | MERCK PATENT GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | MERCK PATENT GMBH (DE) | 2003-03-06 | — | — | US | disclosed |
| EP-1254133-A2 | INDOL-3-YL DERIVATIVES | MERCK PATENT GmbH (DE) | 2002-11-06 | — | — | EP | disclosed |
| EP-1124824-A1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GmbH (DE) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001058893-A2 | INDOL-3-YL DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2001-08-16 | — | — | WO | disclosed |
| WO-2000026212-A1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | IGF1R, IDO1, ITGB3 | FFAR2 403/4885PTGES 2067/4885FDPS 4494/4885 |
| US-20040138284-A1 | Indol-3-yl derivatives | ITGB3, ITGB1, IGF1R | FFAR2 1121/4885PTGES 1330/4885FDPS 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.